z-logo
open-access-imgOpen Access
Why Does Pnemococcus Kill?
Author(s) -
Yves Bergeron,
Michel G. Bergeron
Publication year - 1999
Publication title -
canadian journal of infectious diseases and medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1918-1493
pISSN - 1712-9532
DOI - 10.1155/1999/182623
Subject(s) - geography
Acute lower respiratory tract infections remain the most common cause of death due to infection worldwide, and Streptococcuspneumoniae is responsible for approximately 30% of all cases of community-acquired pneumonia. While manyvirulence factors have been associated with fatal pneumococcal pneumonia. there is growing evidence that some componentsof the immune response contribute significantly to the high mortality rate. This paper reviews the major bacterialvirulence factors and pathogenesis steps that characterize fatal pneumococcal pneumonia, with a focus on the inflammationthat was observed from the initial infection to death in an experimental murine pneumonia model. These stepsinvolve the successive recruitment of polymorphonuclear neutrophils (PMNs). monocytes and lymphocytes; the pulmonaryand/or systemic release of inflammatoty mediators that characterize the prebacteremic and bacteremic phases ofinfection; and the participation of parenchymal cells in the host response. Although the kinetics of cytokines differ considerablyfrom blood to lung tissue to alveoli, and blood levels do not correlate to tissue levels, the kinetics of tumour necrosisfactor (TNF) and interleukin-6 in blood, as well as TNF and nitric oxide in bronchoalveolar lavage (BAL) fluid aregood indicators of the evolution of the disease. Nitric oxide release is biphasic and corresponds mostly to monocyte recruitmentin BAL fluid and concomitant serious tissue injury. Pneumococci activate leukotriene B4 (LTB4) release. butPMN recruitment is not primarily mediated by LTB4. Bacteremia, leukopenia, thrombocytopenia and lipid peroxidationclosely precede death. Knowledge of the chronology of microbiological and inflammatory events that occur during pneumoniamay help to design appropriate diagnostic tests that could be used to monitor the evolution of this deadly infection.There has been an explosive growth in the use of biological response modifiers that may be given to treatpneumonia. The proper use of these agents requires prior identification of biological markers in humans with pneumonia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom